Philip founded Geneva Network in 2015. His main research interests are the intersection of intellectual property, trade, and health policy. Formerly he was an official at the World Intellectual Property Organization (WIPO) in Geneva, where he worked in its Global Challenges Division on a range of IP and health issues. Prior to his time with WIPO, Philip worked as director of policy for International Policy Network, a UK-based think tank, as well as holding research positions with the Adam Smith Institute and Reform, both in London. He has also worked as a political risk consultant and a management consultant. He is a regular columnist in a wide range of international newspapers and has published a number of academic studies. He holds degrees from the London School of Economics and Durham University (UK). He is also a Senior Fellow at the Institute for Democracy and Economic Affairs, Malaysia.
The biggest Covid-related killer might not be the coronavirus. In many countries, disruption to regular immunization programmes means that easily preventable but potentially fatal diseases such as measles, diphtheria and polio are regaining a foothold.
La demanda sin precedentes por parte de hospitales que están almacenando medicamentos básicos ha causado escasez y aumento de precios a nivel mundial.
Traditional rivals within the life sciences industry have pledged to cooperate by sharing data, patent libraries, and, if necessary, manufacturing capacity.
While researchers in universities and private-sector laboratories work round-the-clock for new treatments and vaccines for Covid-19, physicians rely on a broad cabinet of older medicines to help patients through their darkest hour.
The Covid-19 pandemic has illustrated the importance of global trade for access to all kinds of medical supplies, with many jurisdictions suffering shortages of essential medical goods as a result of various trade barriers.
Health data and digital technologies will be essential for improving global health outcomes beyond the COVID-19 pandemic. Low- and middle-income nations,
At the 73rd World Health Assembly earlier this week, public health officials from dozens of countries gathered — virtually, of course — to discuss strategies to defeat COVID-19.
With around a third of the world’s population in lockdown, humanity desperately needs new treatments to turn the tide against COVID-19.
Separating the cost of biopharmaceutical research and development from the final market price of medicines would misalign incentives, raise bureaucratic costs, and limit innovation.